VERACYTE, INC. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Veracyte reported Q2 2026 total revenue of $150.3M (+15% YoY) and testing revenue of $145.7M (+19% YoY), driven by Decipher growth to $91.9M (+20%) and Afirma growth to $51.2M (+18%). The company launched Prosigna Breast Test and TrueMRD Monitoring Test for bladder cancer, secured first Medicare coverage for TrueMRD, and recorded GAAP net income of $25.5M (17.0% margin) with adjusted EBITDA of $44.0M (29.2% margin). Company raised 2026 total revenue guidance to $590–596M (14–15% growth) and testing revenue guidance to $576–582M (17–18% growth), maintaining adjusted EBITDA margin >26%.
Why this rating
Double-digit revenue growth (+15%), profitability inflection (from loss to $25.5M net income), two product launches, and Medicare reimbursement are meaningful for a $1.7B diagnostics company. However, absolute revenue ($150M quarterly) is modest relative to market cap; event represents solid execution but not transformational.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.